BELLICUM PHARMACEUTICALS, INC
DelistedCIK 1358403fmd_1TD13EMF43R7DTGM0X1AA6NHN5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2023, 40 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 2 | 0 | 0 | 0 | 1 | 7 | 1 | 6 | 2 |
| Cost of revenue | – | – | – | – | 1 | 0 | – | – | – | – |
| Realized investment gains (losses) | 0 | 0 | (0) | 0 | 0 | – | – | – | – | – |
| Gross profit | – | – | – | – | (1) | 1 | – | – | – | – |
| Research and development | 8 | 12 | 34 | 51 | 66 | 72 | 65 | 39 | 24 | 23 |
| Total operating expenses | 10 | 60 | 49 | 69 | 88 | 97 | 95 | 55 | 31 | 28 |
| Operating income | (8) | (58) | (49) | (68) | (87) | (95) | (87) | (52) | (25) | (27) |
| Interest expense | 0 | 2 | 0 | 2 | 4 | 4 | 4 | 3 | 0 | – |
| Other non-operating income (expense) | (0) | (26) | 1 | (1) | (4) | (3) | (25) | 44 | 15 | 2 |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income | (8) | (84) | (49) | (69) | (92) | (98) | (112) | (8) | (10) | (25) |
| Net income to common shareholders | (9) | (85) | (49) | (69) | – | – | – | – | – | – |